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INTRODUCTION
It has been realized in recent years that right ventricular (RV) function is a major determinant of functional state, exercise capacity and survival in patients with pulmonary arterial hypertension (PAH) [1] . However, how to measure RV function and what variables might be most clinically relevant at the bedside remains uncertain [1, 2] The gold standard measure of RV systolic functional adaptation to increased loading conditions is end-systolic elastance (Ees), (or end-systolic pressure (ESP) divided by endsystolic volume (ESV)), corrected for arterial elastance (Ea), (or stroke volume (SV) divided by ESP). The Ees/Ea ratio defines RV-arterial coupling, or the matching of contractility to afterload. Ees is a measure of RV contractility and unlike other measures of RV function is load independent. Ea is a measure of the afterload faced by the RV and incorporates resistance, compliance and impedance of the pulmonary circulation. The optimal balance between RV work and oxygen consumption occurs at an Ees/Ea ratio of 1.5-2 [1, 2] .
The reference method for the determination of Ees requires instantaneous and simultaneous measurements of RV pressure and volume and generation of a family of pressure-volume loops at decreasing venous return [3] . This is not practical at the bedside. However Ees can also be estimated from a single P-V loop [4] . This method relies on the calculation of a maximum RV pressure (Pmax) from the extrapolation of early and late systolic portions of a RV pressure curve and the continuous recording of RV pressure and relative change in volume to define ESP and ESV. From these, Ees and Ea are easily calculated. The estimation of RV-arterial coupling by an Ees/Ea ratio can further be simplified for pressure and expressed as a SV/ESV ratio [5] , ie the volume method. Alternatively the ratio can be simplified for volumes and expressed as Pmax divided by mean pulmonary artery pressure (mPAP), taken as a surrogate for ESP, minus 1 [6] , ie the pressure method. A RV pressure
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5 curve is easily obtained during a right heart catheterization. RV volumes are ideally determined by magnetic resonance imaging (CMR).
From RV volumes it is naturally also easy to calculate a SV and an ejection fraction (EF) as SV/EDV. Cardiac CMR studies have shown that decreased SV and RV EF are predictive of poor outcome [7] , and that a deterioration in RV EF during PAH therapy predicts a poor survival irrespective of improvements in pulmonary vascular resistance (PVR) [8] . However, EF is preload-dependent while Ees/Ea is theoretically not. Therefore, estimates of Ees should be superior in determining clinical state and outcome. Accordingly, a recent study on a limited number of patients referred for investigation of PH showed Ees/Ea estimated by SV/ESV to be an independent predictor of outcome while EF was not [9] .
We therefore investigated the prognostic utility of RV-arterial coupling determined by both the volume and the pressure methods, compared to more usual determinations of EF and right heart catheterization-derived RAP and SV in a large cohort of patients with PAH, and in addition examined changes over time of these measurements with targeted therapies and their impact on survival.
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METHODS
We identified 140 treatment naïve incident cases of PAH diagnosed between January 2004
and April 2014 at the Scottish Pulmonary Vascular Unit, Glasgow. Patients were included after multidisciplinary evaluation based on right heart catheterization, echocardiography, pulmonary function testing and CT scan of thorax. All patients underwent invasive measurements and cardiac CMR within 72 hours and received pulmonary vasodilator therapy in accordance with guidelines [10] . In 84/140 patients, RV pressures traces were available and were manually re-digitised using GetData Graph Digitizer 2.26. A subgroup of 44 patients underwent serial CMR after a minimum of 3 months of PAH therapy. 22 control patients without pulmonary hypertension (defined as a mPAP <25mmHg) who had right heart catheterization and CMR to investigate breathlessness were included to provide reference values for RV-arterial coupling by the two methods.
Cardiac CMR
CMR imaging was performed in the supine position on a 1.5-T magnetic resonance imaging scanner (Sonata Magnetom, Siemens, Erlangen Germany) and images were analysed using the Argus analysis software (Houston, Texas). RV and LV volumes were determined by manual tracing endocardial borders of short axis stack obtained during breath-hold as previously described [11] . CMR variables were indexed for body surface area and adjusted for age.
Calculation of RV-arterial coupling
In those patients for whom RV pressure trace was available for analysis, Ees was calculated using the single beat method [4] . An average RV pressure trace was generated for each patient across a respiratory cycle, typically 4-6 beats. Pmax, the maximum theoretical pressure the ventricle could generate if isovolumetric contraction occurred, was calculated
using a manual sine-wave extrapolation of the early systolic and diastolic portions of the RV pressure curve. ESP was approximated by mPAP [6] . Ees was calculated as the slope of endsystolic pressure volume line, Ees = (Pmax -mPAP) / (RVEDV -RVESV). Arterial elastance (Ea) was estimated by mPAP/(RVEDV -RVESV). RV-arterial coupling (Ees/Ea) was simplified for volumes as Pmax/mPAP -1 (hereafter referred to as the pressure method, Ees/Ea-P), or simplified for pressures as SV/ESV (hereafter referred to as the volume method, SV/ESV) [9] . Stroke volume was calculated as cardiac output measured by thermodilution during the right heart catheterization divided by heart rate or as EDV minus ESV, and indexed for body surface area (SVI).
Statistical analysis
Statistical analysis was performed using SPSS 22 (SPSS Inc, Chicago, IL) and Graphpad Prism Version 5.00 (Graphpad Software, California, USA). Continuous variables were tested for normality using D'Agostino and Pearson omnibus normality test. Normally distributed variables are shown as mean ± standard deviation and non-normally distributed variables as median (IQR). Categorical variables are described by percentage (number) unless otherwise stated. Correlation coefficients were calculated by the Spearman method.
Survival was from date of diagnostic right heart catheter and endpoint was date of either death, lung transplantation or censoring. In those who underwent serial CMR to assess change in RV function, survival was from the date of the second study. Patients were censored if they were lost to follow up or alive at last day of study (4 th August 2014). All cause mortality was used for survival analysis. Survival predictors were determined using a bivariate Cox proportional hazards regression analysis with age. Variables with a p value ≤ 0.2 were considered for multivariate analysis. Survival of patients with decreased SV/ESV in
comparison to those with stable or increased SV/ESV were compared by logrank test. A p value < 0.05 was considered statistically significant throughout.
RESULTS
Population characteristics
Of the 140 PAH patients included in the study, 61 deaths occurred in the follow up period (median survival 2086 days). Table 1 There were no significant differences between SVI calculated as cardiac index/ heart rate or as EDV -ESV (30 ± 10 vs 28 ± 10 mL/m 2 in PAH patients and 43 ± 20 vs 45 ± 15 mL/m 2 in controls, p = 0.428). 6.4 (9) 1.4 (2) 0.7 (1) 63 (53) 31 (26) 5 ( Table 2 shows calculated values of Ees, Ea, Ees/Ea-P and SV/ESV for PAH patients and controls. Ees and Ea were increased in PAH patients, and Ees correlated with levels of mPAP, and inversely with pulmonary vascular compliance (r = 0.574 and r = -0.619, both p<0.001). Both Ees/Ea-P and SV/ESV were lower in PAH patients, and inversely correlated with mPAP, r = -0.345 and -0.607 respectively, both p<0.001. Both Ees/Ea-P and SV/ESV were moderate predictors of 6MWD in the whole cohort, r = 0.261 p = 0.004 and r = 0.271 p = 0.003 respectively, after adjustment for age. RVEF and SV
were both superior predictors of 6MWD r = 0.325 and r = 0.509 respectively, both p<0.001.
NTproBNP moderately correlated with Ees/Ea-P but strongly with SV/ESV, r = -0.325 p = 0.002 and r = -0.777 p<0.001 respectively.
Baseline survival analysis
In the cohort of 84 PAH patients whom had both Ees/Ea-P and SV/ESV measures of RV- Table 4 displays the multivariate model for SV/ESV, and table 5 for RVEF. 
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The Kaplan-Meyer survival curves according to cut off SV/ESV 0.534 and RVEF 32.5% as determined by Youden index from ROC curves are shown in Figure 1 . SV/ESV <0.534 demonstrated 81% sensitivity, 50% specificity and RVEF <32.5% 73% sensitivity and 55% specificity for risk of death at 2 years. Survival was worse in PAH patients with SV/ESV < 0.534 (Logrank p=0.017) or RVEF <32.5% (p=0.04).
Change in SV/ESV with PH therapy
15 deaths occurred in the cohort of 44 patients who underwent interval CMR. 42 PAH patients (27 IPAH, 13 CTDPH, 2 POPH) had follow up CMR performed between 3 and 8 months after initiating PH therapy. SV/ESV, RVEF and SVI increased and RVESVI but not RVEDVI decreased with treatment. Table 6 shows baseline and follow up CMR variables at 3-8 months. 21 patients went on to have a further CMR performed at 12-18 months. 
DISCUSSION
The present results show that CMR imaging of RV volumes allows for the prediction of outcome in PAH by RV function defined either as EF or SV/ESV. In this study, right heart catheterization-derived estimates of RV function such as RAP, SV or PVR or SV/PP did not independently predict outcome. Furthermore, there was no added value of combining invasive measurements of pressure with non-invasive measurements of volumes to assess RV-arterial coupling.
The present study confirms previous reports that RV contractility is increased with either preserved or decreased RV-arterial coupling in severe PH [9, [13] [14] [15] [16] . Gold standard metrics of contractility and afterload in vivo are determined from a family of pressure-volume loops as maximum end-systolic and arterial elastances to determine an Ees/Ea relationship by a simple dimensionless number [1] [2] [3] . This is however difficult to implement at the bedside so simpler surrogates have been developed. The most straightforward are based of Ees/Ea either simplified for volume, the pressure method resulting in Pmax/mPAP-1 or simplified for pressure, the volume method resulting in SV/ESV. The pressure method relies on a Pmax calculation based on the analysis of a RV pressure curve to estimate maximum pressure of an isovolumic beat at EDV [4] , and mPAP assumed equal to ESP [6] . While the pressure method generates Ees/Ea values that are quantitatively in the range of reported by more robust methods [9, [14] [15] [16] , the number of assumptions in the method may result in insufficient precision and explain failure to predict outcome. The volume method rests on the indirect assumptions that Ees is a volume-independent straight line crossing the origin, which is not correct [2, 6, 9] . However, measurements of ESV and EDV by CMR have a high level of accuracy and precision, so that the information content of SV/ESV to estimate Ees/Ea is preserved and predicts outcome, confirming the previous report [9] .
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CMR imaging of RV EF has been previously reported to be a potent predictor of outcome in idiopathic PAH [7, 8] . The only study which compared EF to less preload-dependent SV/ESV showed the latter only to be an independent predictor of outcome, suggesting the less load-dependent measures of RV-arterial coupling might be clinically more relevant than EF [9] . In the present study, both SV/ESV and EF independently predicted outcome. These apparent discrepancies are to be explained by differences in background populations (in the previous report PH of mixed aetiology including group II disease was examined, and not all subjects subsequently received PH therapy) and high degree of colinearity between these measurements.
A right heart catheterization is mandatory for the diagnosis of PH [17] . However, the procedure allows for only an indirect decription of RV function, with RAP to estimate EDV, or preload, mPAP or PVR to estimate afterload, and SV to reflect contractility [2] . In spite of these limitations, RAP, cardiac output and PVR have been reported to predict outcome in PAH [18] [19] [20] [21] [22] [23] . However, this was in studies considering exclusively these invasive measurements [2] . In the present study which combined right heart catheterization and CMR measurements, only imaging of RV function predicted outcome, in keeping with previous report [9] . This result agrees with the notion that imaging provides a more accurate and relevant definition of RV function than a standard right heart catheterization. In the multivariate model with SV/ESV p value for RAP neared significance (although less so when more commonly employed RVEF considered, p=0.103). It is therefore possible that RAP would emerge as statistically significant in a larger population, but it is an invasive measure.
This study suggests that montoring of RV function with non-invasive imaging modalities in addition to being more acceptable to the patient yields stronger prognostic variables.
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While other CMR studies of RV function have also reported on EF to independently predict outcome in IPAH [24] , some rather focused on EDV [25] or ESV [26] . On the other hand, a large number of echocardiographic measures of RV systolic function and/or dimensions, or pericardial effusion [1, 2] and even biomarkers such as circulating brain natriuretic peptide [27, 28] have been shown to predict outcome as well. However, these studies were generally small with a limited number of variables, which limits extrapolation of their results to larger populations evaluated with invasive measurements and different imaging modalities and biomarkers. The resulting confusion is probably clarified by prioritizing the variables which are closest to gold standard measurements of RV function [2] .
Treatment with PH therapies resulted in significant improvement in SV/ESV. In accordance with previous published work, improvements in SV and RVEF were also seen [8, 29, 30] . progressive RV dysfunction (defined by drop in RVEF) was seen and this deterioration was associated with poorer survival. PVR however represents only part of the afterload faced by the RV. Ea describes total RV afterload incorporating both resistive and pulsatile components. This is the first study to analyse the effect of therapy on volumetric measure of RV-arterial coupling in PAH.
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There are several limitations to our study. This was a single centre retrospective observational study. The invasive RV trace analysis required manual digitisation from analogue traces for analysis. The RHC and CMR (and therefore pressure and volumes) were not performed simultaneously. There were however no changes in therapy between measurements. The single beat method employed requires several inherent assumptions, such as the use of a sine wave to approximate the waveform of isovolumetric contraction [31], but despite this Pmax generated from single beat method has shown excellent correlation with Pmax derived from multi-beat PV-loop analysis at varying levels of venous return [4] ., which is the gold standard for measuring RV-arterial coupling and ideally should have been included for comparison. .
These studies were not performed in this study as this would have required alteration of venous return through techniques such as inferior vena cava balloon occlusion with potential for complications and were felt unacceptable risk to the patient. Finally, therapy effect on RV-arterial coupling was solely assessed using CMR as it is not common practice in our centre for patients to routinely undergo haemodynamic monitoring with repeat right heart catheterization. How change in more established invasive measurements of RV-arterial coupling with treatment relates to outcome needs to be confirmed in further study.
CONCLUSION
RV function to predict survival in PAH is best determined by CMR measurements of SV/ESV or EF, without added value of invasively measured RV pressure measurements. 
